Author: Ken Dropiewski

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the third quarter ended September 30, 2022. […]

Cytokinetics Reports Third Quarter 2022 Financial Results

Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil on December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 SEQUOIA-HCM Continuing with Results Expected in 2H 2023; Patient Screening for Cohort 4 of REDWOOD-HCM Closed with Data Expected in 1H 2023 COURAGE-ALS Continuing Following First Interim Analysis, Enrollment Expected to Complete in […]

Cardiac Insight Comments on CMS Announcement of National Payment Rates for Long-Term Continuous ECG (LT-ECG) Monitoring in 2023

Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System BELLEVUE, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., creators of Cardea SOLO™ prescription cardiac sensors and automated electrocardiography (ECG) Analysis Software, shares its perspective on the latest CMS ruling, which provides nationwide physician […]

Viz.ai Launches AI-Powered VizTM Cardio Suite

Comprehensive solution tailored for cardiovascular care teams to improve care pathways and grow referrals CHICAGO & SAN FRANCISCO–(BUSINESS WIRE)–AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS– Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of a full cardiology suite to speed and improve patient access to innovative […]

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

— Positive updates from Phase 1 clinical trial in Danon Disease showed RP-A501 was well tolerated with evidence of durable treatment effect and disease improvement for both pediatric patients and adult patients with up to nine and 36 months of follow-up, respectively— — Phase 2 pivotal study design and endpoint selection for Danon […]

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and clarify certain information contained in the quotation of the Chief Executive Officer. All other […]

Konica Minolta Healthcare Continues to Transform X-ray, Introducing New Systems Featuring Dynamic Digital Radiography at RSNA 2022

WAYNE, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare information technology, announces the introduction of new digital radiography (DR) solutions that will continue to transform the clinical value of X-ray. In 2020, Konica Minolta Healthcare launched Dynamic Digital Radiography (DDR), and […]

Acutus Medical Achieves OEM Qualification Milestone in Sale of Left-Heart Access Portfolio to Medtronic

CARLSBAD, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the Company has achieved the first milestone under the asset purchase agreement of its left-heart […]

CVRx Launches new Barostim NEO2™ Implantable Pulse Generator

The new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms […]